April 6, 2020
COVID-19, GNS561’s Assault begins in France !
Marseille, April 6, 2020 — Genoscience Pharma Starts a phase 2 multicenter study using GNS561,…
Read More
January 13, 2020
ISO9001:2015 Certification for our R&D and Clinical Activities in Oncology
Marseille, January 13, 2020 - Genoscience Pharma, a clinical-stage biotechnology company dedicated to discovering and…
Read More
December 16, 2019
GNS561 to treat pancreas or colorectal cancer with liver metastasis
GENOSCIENCE PHARMA Announces Extension of GNS561 Phase 1/2 Clinical Trial to Patients with Pancreas or…
Read More
November 14, 2019
Outstanding Data on GNS561 in Combination with a PD-1 Inhibitor
Outstanding Data on GNS561 in Combination with a PD-1 Inhibitor to Be Presented at the…
Read More
September 25, 2019
Invest in the Future of Health Biotech, European Biotech Week
Invest in the Future of Health Biotech during the European Biotech Week 2019 (Brussels) …
Read More
June 3, 2019
S.A.B Meeting in Chicago, during ASCO 2019
Scientific Advisory Board Meeting during ASCO 2019 Chicago, USA, June 3, 2019 — Genoscience…
Read More
April 17, 2019
Chaim Hurvitz, New Board of Directors Member
Chaim Hurvitz, New Board of Directors Member Chaim Hurvitz has joined Genoscience Pharma Board…
Read More
December 10, 2018
Most Innovative European Biotech SME for 2018
Most Innovative European Biotech SME for 2018 Bruxelles, Belgium, December 3, 2018 - Company…
Read More
October 5, 2018
Extension to US of GNS561 Clinical Trial
Genoscience Pharma Extends to US its Clinical Trial in Patients with Advanced Liver Cancers …
Read More
June 4, 2018
S.A.B. Meeting in Chicago, during ASCO 2018
Scientific Advisory Board Meeting during ASCO 2018 Chicago, USA, June 4, 2018 — During…
Read More
